216 related articles for article (PubMed ID: 22884661)
1. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.
Papaneri AB; Wirblich C; Cooper K; Jahrling PB; Schnell MJ; Blaney JE
Vaccine; 2012 Sep; 30(43):6136-41. PubMed ID: 22884661
[TBL] [Abstract][Full Text] [Related]
2. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.
Blaney JE; Wirblich C; Papaneri AB; Johnson RF; Myers CJ; Juelich TL; Holbrook MR; Freiberg AN; Bernbaum JG; Jahrling PB; Paragas J; Schnell MJ
J Virol; 2011 Oct; 85(20):10605-16. PubMed ID: 21849459
[TBL] [Abstract][Full Text] [Related]
3. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
Blaney JE; Marzi A; Willet M; Papaneri AB; Wirblich C; Feldmann F; Holbrook M; Jahrling P; Feldmann H; Schnell MJ
PLoS Pathog; 2013; 9(5):e1003389. PubMed ID: 23737747
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.
Willet M; Kurup D; Papaneri A; Wirblich C; Hooper JW; Kwilas SA; Keshwara R; Hudacek A; Beilfuss S; Rudolph G; Pommerening E; Vos A; Neubert A; Jahrling P; Blaney JE; Johnson RF; Schnell MJ
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S414-24. PubMed ID: 26063224
[TBL] [Abstract][Full Text] [Related]
5. Genetically modified rabies virus-vectored Ebola virus disease vaccines are safe and induce efficacious immune responses in mice and dogs.
Shuai L; Wang X; Wen Z; Ge J; Wang J; Zhao D; Bu Z
Antiviral Res; 2017 Oct; 146():36-44. PubMed ID: 28822816
[TBL] [Abstract][Full Text] [Related]
6. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
7. Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice.
Lehrer AT; Wong TS; Lieberman MM; Humphreys T; Clements DE; Bakken RR; Hart MK; Pratt WD; Dye JM
Vaccine; 2018 May; 36(22):3090-3100. PubMed ID: 28216187
[TBL] [Abstract][Full Text] [Related]
8. Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.
Papaneri AB; Bernbaum JG; Blaney JE; Jahrling PB; Schnell MJ; Johnson RF
Virus Res; 2015 Feb; 197():54-8. PubMed ID: 25481284
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
10. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
11. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.
Konduru K; Bradfute SB; Jacques J; Manangeeswaran M; Nakamura S; Morshed S; Wood SC; Bavari S; Kaplan GG
Vaccine; 2011 Apr; 29(16):2968-77. PubMed ID: 21329775
[TBL] [Abstract][Full Text] [Related]
12. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
[TBL] [Abstract][Full Text] [Related]
13. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
14. Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge.
Kurup D; Fisher CR; Smith TG; Abreu-Mota T; Yang Y; Jackson FR; Gallardo-Romero N; Franka R; Bronshtein V; Schnell MJ
J Infect Dis; 2019 Sep; 220(9):1521-1528. PubMed ID: 31374568
[TBL] [Abstract][Full Text] [Related]
15. An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.
Johnson RF; Kurup D; Hagen KR; Fisher C; Keshwara R; Papaneri A; Perry DL; Cooper K; Jahrling PB; Wang JT; Ter Meulen J; Wirblich C; Schnell MJ
J Infect Dis; 2016 Oct; 214(suppl 3):S342-S354. PubMed ID: 27456709
[TBL] [Abstract][Full Text] [Related]
16. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.
Papaneri AB; Wirblich C; Cann JA; Cooper K; Jahrling PB; Schnell MJ; Blaney JE
Virology; 2012 Dec; 434(1):18-26. PubMed ID: 22889613
[TBL] [Abstract][Full Text] [Related]
17. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
18. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.
Hensley LE; Mulangu S; Asiedu C; Johnson J; Honko AN; Stanley D; Fabozzi G; Nichol ST; Ksiazek TG; Rollin PE; Wahl-Jensen V; Bailey M; Jahrling PB; Roederer M; Koup RA; Sullivan NJ
PLoS Pathog; 2010 May; 6(5):e1000904. PubMed ID: 20502688
[TBL] [Abstract][Full Text] [Related]
20. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
Callendret B; Vellinga J; Wunderlich K; Rodriguez A; Steigerwald R; Dirmeier U; Cheminay C; Volkmann A; Brasel T; Carrion R; Giavedoni LD; Patterson JL; Mire CE; Geisbert TW; Hooper JW; Weijtens M; Hartkoorn-Pasma J; Custers J; Grazia Pau M; Schuitemaker H; Zahn R
PLoS One; 2018; 13(2):e0192312. PubMed ID: 29462200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
